Literature DB >> 8735616

An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret.

J A Rudd1, R J Naylor.   

Abstract

1. Cisplatin, 5 mg kg-1, i.p., administered as a single treatment, induced an acute (day 1) and delayed (days 2 and 3) emetic response in the ferret that was used to investigate the potential anti-emetic activity of ondansetron and dexamethasone and their interaction over a three day period. 2. Ondansetron, 1 mg kg-1, i.p., administered three times per day in two experiments, antagonized significantly the retching and vomiting that occurred on days 1 and 2 by 60-76 and 73-84%. On the third day of treatment there was a trend for a 38% reduction in one experiment and a 74% reduction in the other. 3. There was a trend for dexamethasone, 1 mg kg-1, i.p., administered as a single daily injection for three days, to reduce by 37% the retching and vomiting response that occurred on day 1, the reduction of 77% on day 2 achieved significance and dexamethasone non-significantly increased the retching and vomiting response by 46% on day 3. However, dexamethasone 1 mg kg-1 i.p. administered three times per day for three days significantly reduced the retching + vomiting response by 85, 97 and 86% on days 1, 2 and 3 respectively. 4. The combination of dexamethasone, 1 mg kg-1, i.p., as single daily injections with ondansetron, 1 mg kg-1, i.p., administered three times per day improved the control of the retching and vomiting response, significantly reducing the total numbers of retches and vomits by more than 70% over a three day period. The combination of dexamethasone (1.0 mg kg-1) and ondansetron (1.0 mg kg-1), both administered three times daily, abolished cisplatin-induced emesis over the three day period. 5. The three times per day administration of ondansetron, 1 mg kg-1, i.p., plus dexamethasone, 1 mg kg-1, i.p., administered only on day 1 prevented day 1 emesis but did not modify the retching and vomiting that occurred on days 2 and 3. 6. The present results indicate that ondansetron and dexamethasone significantly reduce cisplatin-induced emesis in the ferret during both the acute and delayed phase; drug/co-treatment can exert an additive action to abolish cisplatin-induced emesis. The ferret model may be useful to detect anti-emetic drug action for treatment of chemotherapy-induced acute and delayed emesis in man.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735616      PMCID: PMC1909635          DOI: 10.1111/j.1476-5381.1996.tb15388.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

Review 1.  Neuropharmacology of emesis induced by anti-cancer therapy.

Authors:  P L Andrews; W G Rapeport; G J Sanger
Journal:  Trends Pharmacol Sci       Date:  1988-09       Impact factor: 14.819

2.  Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret.

Authors:  J A Rudd; R J Naylor
Journal:  Neuropharmacology       Date:  1994-12       Impact factor: 5.250

3.  Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.

Authors:  D B Smith; E S Newlands; G J Rustin; R H Begent; N Howells; B McQuade; K D Bagshawe
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

Review 4.  Adrenal corticosteroids as antiemetics during cancer chemotherapy.

Authors:  R J Cersosimo; D D Karp
Journal:  Pharmacotherapy       Date:  1986 May-Jun       Impact factor: 4.705

5.  5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.

Authors:  G A Higgins; G J Kilpatrick; K T Bunce; B J Jones; M B Tyers
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

6.  Effects of steroids on postoperative nausea and vomiting.

Authors:  M R Mataruski; N A Keis; D J Smouse; M L Workman
Journal:  Nurse Anesth       Date:  1990-12

7.  Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients.

Authors:  J B Chalk; K Ridgeway; T Brophy; J D Yelland; M J Eadie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

8.  The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret.

Authors:  J A Rudd; K T Bunce; R J Naylor
Journal:  Neuropharmacology       Date:  1996-01       Impact factor: 5.250

9.  Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret.

Authors:  J Hawthorn; D Cunningham
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

Authors:  J Bermudez; E A Boyle; W D Miner; G J Sanger
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more
  15 in total

1.  The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.

Authors:  T Yoshikawa; N Yoshida; M Oka
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

Authors:  Camilo Rojas; Ying Li; Jie Zhang; Marigo Stathis; Jesse Alt; Ajit G Thomas; Sergio Cantoreggi; Silvia Sebastiani; Claudio Pietra; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2010-08-19       Impact factor: 4.030

3.  The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret.

Authors:  J A Rudd; C C Jordan; R J Naylor
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 4.  Regulation of nausea and vomiting by cannabinoids.

Authors:  Linda A Parker; Erin M Rock; Cheryl L Limebeer
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

5.  Cisplatin-induced early and delayed emesis in the pigeon.

Authors:  S Tanihata; H Igarashi; M Suzuki; T Uchiyama
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Cisplatin increases the number of enterochromaffin cells containing substance P in rat intestine.

Authors:  Yusuke Obara; Takuji Machida; Yuho Takano; Saki Shiga; Asami Suzuki; Naoya Hamaue; Kenji Iizuka; Masahiko Hirafuji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-15       Impact factor: 3.000

7.  A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.

Authors:  Erin M Rock; Cheryl L Limebeer; Roshan Navaratnam; Martin A Sticht; Natasha Bonner; Kristin Engeland; Rachel Downey; Heather Morris; Meagan Jackson; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2014-03-05       Impact factor: 4.530

8.  Cisplatin-induced gastric dysrhythmia and emesis in dogs and possible role of gastric electrical stimulation.

Authors:  Xiaoyun Yu; Jie Yang; Xiaohua Hou; Kan Zhang; Wei Qian; J D Z Chen
Journal:  Dig Dis Sci       Date:  2008-08-27       Impact factor: 3.199

Review 9.  Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists.

Authors:  N Percie du Sert; J A Rudd; C C Apfel; P L R Andrews
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-28       Impact factor: 3.333

10.  A Dunnione Compound MB12662 Improves Cisplatin-Induced Tissue Injury and Emesis.

Authors:  Dongsun Park; In Geun Jo; Ja Young Jang; Tae Hwan Kwak; Sang Ku Yoo; Jeong Hee Jeon; Ehn-Kyoung Choi; Seong Soo Joo; Okjin Kim; Yun-Bae Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-09-01       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.